Results 11 to 20 of about 169 (91)

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study [PDF]

Научно-практическая ревматология, 2021
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX)
V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii   +15 more
doaj   +4 more sources

Efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis [PDF]

Терапевтический архив
Aim. Evaluation in real clinical practice of the effectiveness and safety of levilimab therapy in patients with highly and moderately active rheumatoid arthritis (RA). Materials and methods.
Elena V. Bolotova, Evgeniya V. Yakovleva, Ekaterina K. Ilinykh, Тatiana A. Rassovskaya   +3 more
doaj   +3 more sources

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm

Фармакоэкономика, 2021
Aim. The study aimed to assess the economic effect of biological therapy with anti-interleukin (IL)-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm.Materials and Methods.
M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov   +2 more
doaj   +4 more sources

High efficacy and retention rate of levilimab in the treatment of patients with rheumatoid arthritis in real-life practice

Научно-практическая ревматология
Previously published results of a retrospective analysis showed that switching to levilimab from other interleukin 6 receptor inhibitor (iIL6R) allows maintaining the achieved effect, and in some cases, increasing the effectiveness of treatment.
A. I. Zagrebneva, E. N. Simonova, Yu. A. Gavrikova, V. V. Dolgov, G. A. Togizbayev   +4 more
doaj   +2 more sources

Steroid-sparing effect of levilimab in rheumatoid arthritis in real practice

Терапевтический архив
Aim. Evaluation in real clinical practice steroid-sparing effect of levilimab therapy in patients with highly and moderately active rheumatoid arthritis (RA). Materials and methods.
Larisa V. Ivanova, Ekaterina Yu. Akulinushkina, Anastasia N. Vedekhina, Nuriya A. Garaeva, Aliya B. Rashitova, Nikita M. Taratorkin   +5 more
doaj   +2 more sources

Evaluation of the efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis in real practice

Терапевтический архив
Aim. To evaluate the efficacy and safety of levilimab (LVL) in patients with rheumatoid arthritis (RA) in real clinical practice. Materials and methods.
Elvina R. Myasoutova, Alina R. Iuskaeva, Liana S. Kostakova, Elena V. Sukhorukova, Rifkat Z. Abdrakipov, Diana I. Abdulganieva, Nikita M. Taratorkin   +6 more
doaj   +3 more sources

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study

Современная ревматология
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL ...
A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, M. L. Goldman, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, A. I. Zagrebneva, L. V. Ivanova, A. K. Karibova, I. V. Menshikova, O. N. Mironenko, M. P. Mikhailova, N. E. Nikulenkova, I. M. Patrikeeva, T. V. Plaksina, G. R. Savvina, R. R. Samigullina, L. E. Sarantseva, J. V. Usacheva, O. P. Ukhanova, G. F. Fatkhullina, A. L. Chudinov, I. A. Shafieva, S. P. Yakupova   +27 more
doaj   +2 more sources

Does Vilobelimab in Combination With Tocilizumab, Levilimab, or Baricitinib Improve Mortality in Patients With COVID-19 ARDS?Take-Home Points

CHEST Critical Care
Background: Vilobelimab, unlike upstream complement inhibitors, blocks C5a without altering the membrane attack complex. Vilobelimab demonstrated significant mortality benefit in intubated patients with COVID-19 ARDS in a placebo-controlled study ...
Andrew F. Shorr, MD, Alexander P.J. Vlaar, MD, PhD, Endry H.T. Lim, MD, PhD, Roy F. Chemaly, MD, Bruce P. Burnett, PhD, Simon Rückinger, PhD, Robert Zerbib, MSc, Renfeng Guo, MD, Niels Riedemann, MD, PhD, Diederik van de Beek, MD, PhD, Christian Sandrock, MD   +10 more
doaj   +2 more sources

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. [PDF]

Inflamm Res, 2021
Abstract Objective and design The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. Subjects The study included 217 patients.
Lomakin NV, Bakirov BA, Protsenko DN, Mazurov VI, Musaev GH, Moiseeva OM, Pasechnik ES, Popov VV, Popov VV, Smolyarchuk EA, Gordeev IG, Gilyarov MY, Fomina DS, Seleznev AI, Linkova YN, Dokukina EA, Eremeeva AV, Pukhtinskaia PS, Morozova MA, Zinkina-Orikhan AV, Lutckii AA.   +20 more
europepmc   +4 more sources

Levilimab in patients with COVID-19 in real-life practice [PDF]

Clinical pharmacology and therapy, 2021
To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.
V.V. Mladov, P.S. Pukhtinskaia, D.N. Khobotnikov, E.A. Bezuglaya, M.A. Uyanaeva, G.Yu. Melik-Ogandzhanyan, G.G. Melkonyan, V.V. Strizheletskiy, T.A. Meleshkevich, S.R. Fridman, T.V. Bezuglaya, P.A. Plesovskiy, K.A. Lytkina, I.G. Ivanov, E.V. Tavlueva   +14 more
openaire   +1 more source